中华医学杂志(英文版)
中華醫學雜誌(英文版)
중화의학잡지(영문판)
CHINESE MEDICAL JOURNAL
2002年
3期
402-404
,共3页
孙宜萍%毛敏伟%孙丽华%冯缨缨%杨建芬%沈佩华
孫宜萍%毛敏偉%孫麗華%馮纓纓%楊建芬%瀋珮華
손의평%모민위%손려화%풍영영%양건분%침패화
脱氢表雄酮%脱氢表雄酮硫酸酯%骨质疏松症%骨密度
脫氫錶雄酮%脫氫錶雄酮硫痠酯%骨質疏鬆癥%骨密度
탈경표웅동%탈경표웅동류산지%골질소송증%골밀도
dehydroepiandrosterone%dehydroepiandrosterone sulfate%osteoporosis
目的 观察脱氢表雄酮硫酸酯治疗男性骨质疏松症的疗效、安全性. 方法 随机单盲对照观察脱氢表雄酮硫酸酯(DHEAS)服用六个月前后骨密度（BMD）、血生化指标、骨吸收指标和骨形成指标,副作用等方面的变化.结果 治疗后治疗组脱氢表雄酮硫酸酯(DHEAS)、类胰岛素生长因子-Ⅰ（IGF-Ⅰ）较治疗前分别提高（93.75±16.1）%、(17.71±4.2)%,较对照组明显提高（P<0.01）.腰2、腰3、腰4的骨密度（BMD）较治疗前分别提高（2.65±0.62）%、（2.70±0.48）%、（3.10±0.41）%,腰2-4较治疗前提高（2.82±0.37）%,股骨颈的BND较治疗前提高（2.32±0.32）%.腰2、腰3、腰4、腰2-4、股骨颈的BMD上升幅度较大与对照组差别有显著性（P<0.05 ,0.01）.游离睾丸酮（FT）、雌二醇（E2）、前列特异抗原（PSA）则无明显影响. 结论 脱氢表雄酮硫酸酯治疗男性骨质疏松症的疗效安全可靠,无不良反应.
目的 觀察脫氫錶雄酮硫痠酯治療男性骨質疏鬆癥的療效、安全性. 方法 隨機單盲對照觀察脫氫錶雄酮硫痠酯(DHEAS)服用六箇月前後骨密度（BMD）、血生化指標、骨吸收指標和骨形成指標,副作用等方麵的變化.結果 治療後治療組脫氫錶雄酮硫痠酯(DHEAS)、類胰島素生長因子-Ⅰ（IGF-Ⅰ）較治療前分彆提高（93.75±16.1）%、(17.71±4.2)%,較對照組明顯提高（P<0.01）.腰2、腰3、腰4的骨密度（BMD）較治療前分彆提高（2.65±0.62）%、（2.70±0.48）%、（3.10±0.41）%,腰2-4較治療前提高（2.82±0.37）%,股骨頸的BND較治療前提高（2.32±0.32）%.腰2、腰3、腰4、腰2-4、股骨頸的BMD上升幅度較大與對照組差彆有顯著性（P<0.05 ,0.01）.遊離睪汍酮（FT）、雌二醇（E2）、前列特異抗原（PSA）則無明顯影響. 結論 脫氫錶雄酮硫痠酯治療男性骨質疏鬆癥的療效安全可靠,無不良反應.
목적 관찰탈경표웅동류산지치료남성골질소송증적료효、안전성. 방법 수궤단맹대조관찰탈경표웅동류산지(DHEAS)복용륙개월전후골밀도（BMD）、혈생화지표、골흡수지표화골형성지표,부작용등방면적변화.결과 치료후치료조탈경표웅동류산지(DHEAS)、류이도소생장인자-Ⅰ（IGF-Ⅰ）교치료전분별제고（93.75±16.1）%、(17.71±4.2)%,교대조조명현제고（P<0.01）.요2、요3、요4적골밀도（BMD）교치료전분별제고（2.65±0.62）%、（2.70±0.48）%、（3.10±0.41）%,요2-4교치료전제고（2.82±0.37）%,고골경적BND교치료전제고（2.32±0.32）%.요2、요3、요4、요2-4、고골경적BMD상승폭도교대여대조조차별유현저성（P<0.05 ,0.01）.유리고환동（FT）、자이순（E2）、전렬특이항원（PSA）칙무명현영향. 결론 탈경표웅동류산지치료남성골질소송증적료효안전가고,무불량반응.
Objective To study the effect of dehydroepiandrosterone sulfate (DHEAS) treatment of osteoporosis in men with TBMD≥2.5SD. Methods Eighty-six patients were randomly divided into two groups: treatment group (n=44) and control group (n=42). DHEAS (100?mg q.d.) was given to the treatment group for 6 months. Bone mineral density, (BMD), biochemical markers of bone absorption and formation and other serum biochemical markers were measured before and after DHEAS treatment. Drug side effects were also evaluated. Results After oral administration of DHEAS (100?mg q.d.) for 6 months, the serum concentrations of DHEAS and IGF-Ⅰ in the treatment group were 93.75%±16.1% and 17.71%±4.2% higher respectively than those in the control group (P<0.01). The BMD of L2, L3, L4, L2-4 and Neck sections increased in the treatment group by 2.65%±0.65%, 2.70%±0.48%, 3.10%±0.41%, 2.82%±0.37% and 2.32%±0.31%, respectively, as compared with that the control group (P<0.05 or 0.01). No significant changes were observed in serum FT, E2 and PSA concentrations in the treatment group as compared with the control group. Conclusion The treatment of osteoporosis in men with DHEAS is safe and effective.
